Viking expects to advance the oral version of its experimental obesity drug VK2735 into late-stage study in the third quarter ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses ...

Viking Therapeutics (VKTX) has put its clinical pipeline in the spotlight around its Q4 2025 earnings release, with fresh trial updates on obesity candidate VK2735 and an upcoming amylin agonist ...

As of Thursday, February 12, Viking Therapeutics, Inc.’s VKTX share price has surged by 13.80%, which has investors questioning if this is right time to sell.

Viking Therapeutics (VKTX) stock jumps as Wall Street welcomes the company's Q4 2025 results which includes pipeline updates on its obesity drug, VK2735. Read more here.

Viking Therapeutics (NASDAQ: VKTX) has outperformed the market over the past 10 years by 20.04% on an annualized basis producing an average annual return of 33.54%. Currently, Viking Therapeutics has ...

Lian indicated the oral VK2735 program is expected to advance into Phase III for obesity, with initiation targeted for the third quarter of 2026. "We currently expect to initiate this program in the ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against the ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Viking, with the company achieving multiple important milestones with our expanding obesity pipeline. With the subcutaneous ...